Clinical trials: Fungal Infection
Hidradenitis Suppurativa (HS)
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label…
- Trial name
- TibuSHIELD (NCT06993610)
- Testing
- Tibulizumab Dose A, Tibulizumab Dose B
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 247 people
- Sponsor
- Zura Bio Inc
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Lyme Disease
A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease
This study will evaluate Advanced Laboratory Services Borrelia diagnostic test by culturing Borrelia spirochetes from human serum in subjects with early or late Lyme disease. This is an 8 month study.
- Trial name
- ALSIBDT (NCT02741609)
- Testing
- Borrelia Diagnostic Test
- Where
- 16 sites in United States
- Volunteers
- 218 people
- Sponsor
- Advanced Laboratory Services, Inc.
Candidiasis, Oral, HIV Infections
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.
- Trial name
- NCT00002133
- Testing
- Itraconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen, LP
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- Trial name
- NCT04530838
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 38 sites in Japan
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Pulmonary Aspergillosis
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
- Trial name
- SCYNERGIA (NCT03672292)
- Testing
- SCY-078, Voriconazole
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Scynexis, Inc.
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Bacteremia
Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates
This is a performance and reproducibility study to validate new or updated antimicrobials on the Accelerate PhenoTest™ BC kit. The data from this study will be used to support the submission to the FDA for clearance in the US and…
- Trial name
- NCT04295915
- Testing
- Specimens that meet inclusion criteria
- Where
- 3 sites in United States
- Volunteers
- 731 people, healthy volunteers welcome
- Sponsor
- Accelerate Diagnostics, Inc.
Pneumococcal Infections
Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
This study is a combination of a Phase I and Phase III study design. The Phase I portion is an open-label, controlled study to evaluate the safety of 7vPnC in healthy Chinese infants.
- Trial name
- NCT00488826
- Testing
- 7-valent pneumococcal conjugate vaccine, Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Melioidosis
Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
The study investigates the effect of 14 days of twice daily doses of ARV-1801 or placebo in combination with meropenem or ceftazidime in patients hospitalized with melioidosis.
- Trial name
- NCT05105035
- Testing
- Ceftazidime or meropenem, ARV-1801
- Where
- 5 sites in Thailand
- Volunteers
- 125 people
- Sponsor
- Arrevus Inc.
Meningitis, Meningococcal Disease
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
The aim of the study is to assess safety and immunogenicity of a single dose of Menactra® in support of registration of the vaccine in South Korea.
- Trial name
- NCT01642589
- Testing
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Where
- 7 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Bacterial
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
This study is open-label, randomized two-way cross-over study to determine if cefixime 200 mg/5 mL powder for suspension (test formulation: SKF101804) is bioequivalent to cefixime 200 mg/5 mL suspension reference formulation.
- Trial name
- NCT03408392
- Testing
- Test formulation A, Reference formulation B
- Where
- South Africa
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Invasive Aspergillosis
Olorofim Aspergillus Infection Study
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus…
- Trial name
- OASIS (NCT05101187)
- Testing
- Olorofim, AmBisome®
- Where
- 143 sites in United States, Australia and 19 more
- Volunteers
- 225 people
- Sponsor
- F2G Ltd
Infections, Meningococcal
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612
This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine 134612 when given in an experimental co-administration versus vaccine 134612 alone and versus the experimental co-administration alone in…
- Trial name
- NCT00465816
- Testing
- Nimenrix (Meningococcal vaccine 134612), Twinrix
- Where
- 6 sites in Denmark, Sweden
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacteremia
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects…
- Trial name
- NCT02208063
- Testing
- Telavancin, Vancomycin, Daptomycin
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Cumberland Pharmaceuticals
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving…
- Trial name
- NCT06720038
- Testing
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Meningitis, Meningococcal
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease
- Trial name
- NCT00297687
- Testing
- MnB rLP2086
- Where
- 3 sites in Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infections
TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
The purpose of this Phase I, open-label, single sequence drug-drug interaction trial in human immunodeficiency virus-type 1 infected patients is to investigate the potential interaction between steady-state nevirapine (NVP) 200…
- Trial name
- NCT00910806
- Testing
- TMC207; nevirapine
- Where
- South Africa
- Volunteers
- 16 people
- Sponsor
- Tibotec BVBA
Pneumococcal Infections, Pneumonia, Pneumococcal
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.
- Trial name
- NCT02116998
- Testing
- GEN-004 with Aluminum Hydroxide Adjuvant, Streptococcus pneumoniae inoculation
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Tuberculosis Identification.
Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)
A study to determine bioequivalence of PPD material versus Reference Standard.
- Trial name
- 02 (NCT01798121)
- Testing
- To compare new PPD to reference standard material, Reference standard
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- JHP Pharmaceuticals LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.